NASDAQ:BYSI - BeyondSpring Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.67
  • Forecasted Upside: 233.33 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$9.80
▼ -0.26 (-2.58%)
1 month | 3 months | 12 months
Get New BeyondSpring Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BYSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BYSI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$32.67
▲ +233.33% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for BeyondSpring in the last 3 months. The average price target is $32.67, with a high forecast of $43.00 and a low forecast of $25.00. The average price target represents a 233.33% upside from the last price of $9.80.
Buy
The current consensus among 3 polled investment analysts is to buy stock in BeyondSpring. This rating has held steady since December 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2021HC WainwrightDowngradeBuy ➝ NeutralLow
i
Rating by J. Pantginis at HC Wainwright
1/11/2021Bank of AmericaInitiated CoverageBuy$25.00High
i
12/28/2020Evercore ISIInitiated CoverageOutperform$30.00N/A
i
11/24/2020HC WainwrightLower Price TargetBuy$46.00 ➝ $43.00Low
i
Rating by Joseph Pantginis at HC Wainwright
6/15/2020HC WainwrightReiterated RatingBuy$30.00 ➝ $46.00High
i
Rating by Joseph Pantginis at HC Wainwright
6/9/2020HC WainwrightReiterated RatingBuy$30.00Low
i
Rating by Joseph Pantginis at HC Wainwright
4/29/2020HC WainwrightReiterated RatingBuy$30.00Low
i
Rating by Joseph Pantginis at HC Wainwright
3/30/2020HC WainwrightLower Price TargetBuy$41.00 ➝ $30.00Low
i
3/19/2020William BlairReiterated RatingBuyHigh
i
Rating by A. Hsieh at William Blair
2/7/2020Jefferies Financial GroupInitiated CoverageBuy$25.00Low
i
1/10/2020William BlairReiterated RatingBuyHigh
i
Rating by A. Hsieh at William Blair
1/10/2020Nomura SecuritiesInitiated CoverageBuy$34.00High
i
12/3/2019William BlairInitiated CoverageOutperformLow
i
Rating by A. Hsieh at William Blair
9/18/2019HC WainwrightReiterated RatingBuy$41.00Medium
i
7/10/2019HC WainwrightReiterated RatingBuy$60.00Low
i
4/30/2019Maxim GroupDowngradeBuy ➝ HoldHigh
i
3/4/2019HC WainwrightReiterated RatingBuyMedium
i
Rating by Joseph Pantginis at HC Wainwright
12/21/2018HC WainwrightSet Price TargetBuy$60.00Low
i
Rating by Joseph Pantginis at HC Wainwright
12/6/2018HC WainwrightReiterated RatingBuy$60.00Low
i
Rating by Joseph Pantginis at HC Wainwright
10/25/2018Maxim GroupReiterated RatingBuy$48.00 ➝ $35.00Medium
i
10/24/2018HC WainwrightSet Price TargetBuy$60.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
6/22/2018HC WainwrightReiterated RatingBuy$60.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
6/21/2018Maxim GroupReiterated RatingBuy ➝ Buy$52.00 ➝ $48.00Medium
i
Rating by Jason McCarthy at Maxim Group
6/5/2018HC WainwrightSet Price TargetBuy$60.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/17/2018Maxim GroupReiterated RatingBuy$52.00Medium
i
Rating by Jason McCarthy at Maxim Group
4/3/2018HC WainwrightSet Price TargetBuy$60.00Low
i
Rating by Joseph Pantginis at HC Wainwright
4/3/2018Maxim GroupSet Price TargetBuy$52.00Low
i
Rating by Jason McCarthy at Maxim Group
3/19/2018HC WainwrightSet Price TargetBuy$60.00Low
i
Rating by Joseph Pantginis at HC Wainwright
3/19/2018Maxim GroupSet Price TargetBuy$52.00Low
i
Rating by Jason McCarthy at Maxim Group
3/1/2018HC WainwrightSet Price TargetBuy$60.00Low
i
Rating by Joseph Pantginis at HC Wainwright
2/7/2018Maxim GroupReiterated RatingBuy$52.00Low
i
Rating by Jason Kolbert at Maxim Group
12/15/2017HC WainwrightSet Price TargetBuy$60.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/14/2017Maxim GroupSet Price TargetBuy$52.00Low
i
Rating by Jason Kolbert at Maxim Group
12/5/2017Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$56.00Medium
i
Rating by V. Bernardino at Seaport Global Securities
12/4/2017HC WainwrightSet Price TargetBuy$60.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
11/30/2017Maxim GroupSet Price TargetBuy$52.00Low
i
Rating by Jason Kolbert at Maxim Group
10/27/2017Maxim GroupReiterated RatingBuy$52.00N/A
i
Rating by Gabrielle Zhou at Maxim Group
10/26/2017HC WainwrightSet Price TargetBuy$60.00N/A
i
Rating by J. Pantginis at HC Wainwright
8/22/2017Maxim GroupInitiated CoverageBuy ➝ Buy$52.00Low
i
Rating by Gabrielle Zhou at Maxim Group
8/21/2017HC WainwrightReiterated RatingBuy$50.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
7/14/2017Rodman & RenshawBoost Price TargetBuy ➝ Buy$43.00 ➝ $50.00Medium
i
5/31/2017HC WainwrightSet Price TargetBuy$43.00High
i
Rating by Joseph Pantginis at HC Wainwright
4/4/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$43.00Low
i
(Data available from 4/19/2016 forward)
BeyondSpring logo
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.
Read More

Today's Range

Now: $9.80
$9.55
$10.10

50 Day Range

MA: $11.69
$9.96
$13.26

52 Week Range

Now: $9.80
$9.55
$21.50

Volume

181,500 shs

Average Volume

267,225 shs

Market Capitalization

$383.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of BeyondSpring?

The following sell-side analysts have issued research reports on BeyondSpring in the last twelve months: Bank of America Co., Evercore ISI, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for BYSI.

What is the current price target for BeyondSpring?

3 Wall Street analysts have set twelve-month price targets for BeyondSpring in the last year. Their average twelve-month price target is $32.67, suggesting a possible upside of 233.3%. HC Wainwright has the highest price target set, predicting BYSI will reach $43.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $25.00 for BeyondSpring in the next year.
View the latest price targets for BYSI.

What is the current consensus analyst rating for BeyondSpring?

BeyondSpring currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BYSI will outperform the market and that investors should add to their positions of BeyondSpring.
View the latest ratings for BYSI.

What other companies compete with BeyondSpring?

How do I contact BeyondSpring's investor relations team?

BeyondSpring's physical mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company's listed phone number is 1-646-305-6387 and its investor relations email address is [email protected] The official website for BeyondSpring is www.beyondspringpharma.com.